Impact of tumor heterogeneity of driver mutation-positive lung cancer

• Project/Area Number: 18K07271
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Review Section: Basic Section 50020:Tumor diagnostics and therapeutics-related
• Research Institution: Wakayama Medical University
• Principal Investigator: Hiroaki Akamtsu 和歌山県立医科大学, 医学部, 講師 (10646582)
• Co-Investigator(Kenkyū-buntansha): 山本 信之 和歌山県立医科大学, 医学部, 教授 (60298966) ; 洪 泰浩 和歌山県立医科大学, 医学部, 准教授 (80426519)
• Project Period (FY): 2018-04-01 – 2021-03-31
• Project Status: Completed (Fiscal Year 2020)
• Budget Amount: ¥4,420,000 (Direct Cost: ¥3,400,000、Indirect Cost: ¥1,020,000); Fiscal Year 2020: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000); Fiscal Year 2019: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000); Fiscal Year 2018: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
• Keywords: Liquid biopsy / EGFR遺伝子変異 / 肺癌 / リキッドバイオプシー / 非小細胞肺癌 / 分子標的治療薬 / heterogeneity

Outline of Final Research Achievements

In a multicenter study, we performed digital PCR analysis using tumor-derived DNA (cfDNA) in peripheral blood samples and showed that decline of cfDNA at 4 weeks was correlated with long-term efficacy (Akamatsu H, Lung Cancer 2019). We also reported that a variant of exon19 deletion affected the efficacy (Tokudome N, BMC Cancer 2020).
We enrolled 94 cases in a prospective observational study and confirmed that the sensitivity of digital PCR and high-sensitivity next-generation sequencing was comparable using the first 12 samples. We are still working on the analysis, but it has been slightly slowed due to delays in the supplies caused by the COVID19 pandemic.

Academic Significance and Societal Importance of the Research Achievements

多施設共同研究の結果から、治療早期のcfDNA変化が長期治療効果を予測することを示した。また、従来一括りにされていたEGFR遺伝子変異陽性肺癌がバリアント部位によって異なる治療反応を示すことを報告した。
現在EGFR遺伝子変異陽性と診断された場合の治療法は均一であるが、こうした治療反応のばらつきを加味した場合、治療前や早期の段階でより強度の強い治療が必要になる集団（=早期に治療不応・耐性化する集団）を同定できる可能性がある。

Research Products

• [Journal Article] Efficacy of Osimertinib Plus Bevacizumab vs Osimertinib in Patients With EGFR T790M?Mutated Non?Small Cell Lung Cancer Previously Treated With Epidermal Growth Factor Receptor?Tyrosine Kinase Inhibitor (2021)
  • Author(s): Akamatsu Hiroaki、Toi Yukihiro、Hayashi Hidetoshi、Fujimoto Daichi、Tachihara Motoko、Furuya Naoki、Otani Sakiko、Shimizu Junichi、Katakami Nobuyuki、Azuma Koichi、Miura Naoko、Nishino Kazumi、Hara Satoshi、Teraoka Shunsuke、Morita Satoshi、Nakagawa Kazuhiko、Yamamoto Nobuyuki
  • Journal Title: JAMA Oncology Volume: 7 Issue: 3 Pages: 386-386
  • DOI: 10.1001/jamaoncol.2020.6758
  • Peer Reviewed / Open Access / Int'l Joint Research
• [Journal Article] Phase Ib Study of Osimertinib Plus Ramucirumab in Japanese Lung Cancer Patients With EGFR Mutation (2021)
  • Author(s): AKAMATSU HIROAKI、OZAWA YUICHI、OYANAGI JUN、FUJIMOTO DAICHI、HATA AKITO、KATAKAMI NOBUYUKI、TOMII KEISUKE、MURAKAMI ERIKO、SUGIMOTO TAKEYA、SHIMOKAWA TOSHIO、KOH YASUHIRO、YAMAMOTO NOBUYUKI
  • Journal Title: Anticancer Research Volume: 41 Issue: 2 Pages: 911-917
  • DOI: 10.21873/anticanres.14844
  • Peer Reviewed / Open Access / Int'l Joint Research
• [Journal Article] Sequential therapy of crizotinib followed by alectinib for non-small cell lung cancer harbouring anaplastic lymphoma kinase rearrangement (WJOG9516L): A multicenter retrospective cohort study (2021)
  • Author(s): Ito Kentaro, Yamanaka Takeharu, Fujimoto Daichi, Maeno Ken, Aoki Takuya, Miura Satoru, Akamatsu Hiroaki、Nakagawa Kazuhiko, Yamamoto Nobuyuki
  • Journal Title: European Journal of Cancer Volume: 145 Pages: 183-193
  • DOI: 10.1016/j.ejca.2020.12.026
  • Peer Reviewed / Open Access / Int'l Joint Research
• [Journal Article] Differential significance of molecular subtypes which were classified into EGFR exon 19 deletion on the first line afatinib monotherapy (2020)
  • Author(s): Tokudome Nahomi、Koh Yasuhiro、Akamatsu Hiroaki、Fujimoto Daichi、Okamoto Isamu、Nakagawa Kazuhiko、Hida Toyoaki、Imamura Fumio、Morita Satoshi、Yamamoto Nobuyuki
  • Journal Title: BMC Cancer Volume: 20 Issue: 1 Pages: 103-103
  • DOI: 10.1186/s12885-020-6593-1
  • Peer Reviewed / Open Access / Int'l Joint Research
• [Journal Article] Tumor mutation burden as a biomarker for lung cancer patients treated with pemetrexed and cisplatin (the JIPANG-TR). (2020)
  • Author(s): Sakai K, Tsuboi M, Kenmotsu H, Yamanaka T, Takahashi T, Goto K, Daga H, Ohira T, Ueno T, Aoki T, Nakagawa K, Yamazaki K, Hosomi Y, Kawaguchi K, Okumura N, Takiguchi Y, Sekine A, Haruki T, Yamamoto H, Sato Y, Sugio K
  • Journal Title: Cancer Sci. Volume: 112(1) Issue: 1 Pages: 388-396
  • DOI: 10.1111/cas.14730
  • Peer Reviewed / Open Access / Int'l Joint Research
• [Journal Article] Predicting osimertinib‐treatment outcomes through EGFR mutant‐fraction monitoring in the circulating tumor DNA of EGFR T790M‐positive patients with non‐small cell lung cancer (WJOG8815L) (2020)
  • Author(s): Sakai Kazuko、Takahama Takayuki、Shimokawa Mototsugu、Azuma Koichi、Takeda Masayuki、Kato Terufumi、Daga Haruko、Okamoto Isamu、Akamatsu Hiroaki、Teraoka Shunsuke、Ono Akira、Ohira Tatsuo、Yokoyama Toshihide、Yamamoto Nobuyuki、Nakagawa Kazuhiko、Nishio Kazuto
  • Journal Title: Molecular Oncology Volume: 15 Issue: 1 Pages: 126-137
  • DOI: 10.1002/1878-0261.12841
  • Peer Reviewed / Int'l Joint Research
• [Journal Article] CD24, not CD47, negatively impacts upon response to PD‐1/L1 inhibitors in non?small‐cell lung cancer with PD‐L1 tumor proportion score?<?50 (2020)
  • Author(s): Ozawa Yuichi、Harutani Yuhei、Oyanagi Jun、Akamatsu Hiroaki、Fukuoka Junya、Nakanishi Masanori、Koh Yasuhiro、Yamamoto Nobuyuki
  • Journal Title: Cancer Science Volume: 112 Issue: 1 Pages: 72-80
  • DOI: 10.1111/cas.14705
  • Peer Reviewed / Open Access / Int'l Joint Research
• [Journal Article] Plasma screening for the T790M mutation of EGFR and phase 2 study of osimertinib efficacy in plasma T790M?positive non?small cell lung cancer: West Japan Oncology Group 8815L/LPS study (2020)
  • Author(s): Takahama Takayuki、Akamatsu Hiroaki、Teraoka Shunsuke、Takahashi Toshiaki、Ono Akira、Ohira Tatsuo、Yokoyama Toshihide、Sakai Kazuko、Yamamoto Nobuyuki、Nishio Kazuto、Nakagawa Kazuhiko
  • Journal Title: Cancer Volume: 126 Issue: 9 Pages: 1940-1948
  • DOI: 10.1002/cncr.32749
  • Peer Reviewed / Open Access / Int'l Joint Research
• [Journal Article] Detection of AXL expression in circulating tumor cells of lung cancer patients using an automated microcavity array system (2020)
  • Author(s): Ikeda Mio、Koh Yasuhiro、Teraoka Shunsuke、Sato Koichi、Kanai Kuninobu、Hayata Atsushi、Tokudome Nahomi、Akamatsu Hiroaki、Ozawa Yuichi、Akamatsu Keiichiro、Endo Katsuya、Higuchi Masayuki、Nakanishi Masanori、Ueda Hiroki、Yamamoto Nobuyuki
  • Journal Title: Cancer Medicine Volume: 9 Issue: 6 Pages: 2122-2133
  • DOI: 10.1002/cam4.2846
  • Peer Reviewed / Open Access / Int'l Joint Research
• [Journal Article] Predictive and sensitive biomarkers for thyroid dysfunctions during treatment with immune‐checkpoint inhibitors (2020)
  • Author(s): Kurimoto Chiaki、Inaba Hidefumi、Ariyasu Hiroyuki、Iwakura Hiroshi、Ueda Yoko、Uraki Shinsuke、Takeshima Ken、Furukawa Yasushi、Morita Shuhei、Yamamoto Yuki、Yamashita Shimpei、Katsuda Masahiro、Hayata Atsushi、Akamatsu Hiroaki、Jinnin Masatoshi、Hara Isao、Yamaue Hiroki、Akamizu Takashi
  • Journal Title: Cancer Science Volume: - Issue: 5 Pages: 1468-1477
  • DOI: 10.1111/cas.14363
  • Peer Reviewed / Open Access
• [Journal Article] Immune‐Related Adverse Events by Immune Checkpoint Inhibitors Significantly Predict Durable Efficacy Even in Responders with Advanced Non‐Small Cell Lung Cancer (2019)
  • Author(s): Akamatsu Hiroaki、Murakami Eriko、Oyanagi Jun、Shibaki Ryota、Kaki Takahiro、Takase Eri、Tanaka Masanori、Harutani Yuhei、Yamagata Nao、Okuda Yuka、Furuta Katsuyuki、Sugimoto Takeya、Teraoka Shunsuke、Hayata Atsushi、Tokudome Nahomi、Ozawa Yuichi、Mori Keita、Koh Yasuhiro、Yamamoto Nobuyuki
  • Journal Title: The Oncologist Volume: 25 Issue: 4 Pages: e679-e683
  • DOI: 10.1634/theoncologist.2019-0299
  • Peer Reviewed / Open Access
• [Journal Article] Survival Analysis for Patients with ALK Rearrangement‐Positive Non‐Small Cell Lung Cancer and a Poor Performance Status Treated with Alectinib: Updated Results of Lung Oncology Group in Kyushu 1401 (2019)
  • Author(s): Iwama Eiji、Akamatsu Hiroaki、Morinaga Ryotaro、Akagi Takanori、Shimose Takayuki、Tokunaga Shoji、Yamamoto Nobuyuki、Nakanishi Yoichi、Sugio Kenji、Okamoto Isamu
  • Journal Title: The Oncologist Volume: 25 Issue: 4 Pages: 306-306
  • DOI: 10.1634/theoncologist.2019-0728
  • Peer Reviewed / Open Access
• [Journal Article] Furosemide versus mannitol in Japanese patients with thoracic malignancy who received cisplatin-based chemotherapy using short hydration: study protocol for a randomised controlled trial (2019)
  • Author(s): Murakami Eriko、Akamatsu Hiroaki、Shimokawa Toshio、Wada Kiyoko、Yamamoto Nobuyuki
  • Journal Title: BMJ Open Volume: 9 Issue: 12 Pages: e029057-e029057
  • DOI: 10.1136/bmjopen-2019-029057
  • Peer Reviewed / Open Access
• [Journal Article] Subgroup Analysis of Japanese Patients in a Phase III Study of Atezolizumab in Extensive-stage Small-cell Lung Cancer (IMpower133) (2019)
  • Author(s): Nishio Makoto、Sugawara Shunichi、Atagi Shinji、Akamatsu Hiroaki、Sakai Hiroshi、Okamoto Isamu、Takayama Koichi、Hayashi Hidetoshi、Nakagawa Yuki、Kawakami Tomohisa
  • Journal Title: Clinical Lung Cancer Volume: 20 Issue: 6 Pages: 469-476.e1
  • DOI: 10.1016/j.cllc.2019.07.005
  • Peer Reviewed
• [Journal Article] Phase I safety and pharmacokinetics study of rovalpituzumab tesirine in Japanese patients with advanced, recurrent small cell lung cancer (2019)
  • Author(s): Udagawa Hibiki、Akamatsu Hiroaki、Tanaka Kentaro、Takeda Masayuki、Kanda Shintaro、Kirita Keisuke、Teraoka Shunsuke、Nakagawa Kazuhiko、Fujiwara Yutaka、Yasuda Ikuko、Okubo Sumiko、Shintani Masayuki、Kosloski Matthew P.、Scripture Charity、Tamura Tomohide、Okamoto Isamu
  • Journal Title: Lung Cancer Volume: 135 Pages: 145-150
  • DOI: 10.1016/j.lungcan.2019.07.025
  • Peer Reviewed
• [Journal Article] Summary of the Japanese Respiratory Society statement for the treatment of lung cancer with comorbid interstitial pneumonia (2019)
  • Author(s): Ogura Takashi、Akamatsu Hiroaki、Kenmotsu Hirotsugu、Yanagihara Toyoshi、Yamamoto Nobuyuki、Yamamoto Hiromasa、Gaga Mina、Fong Kwun M.、Powell Charles A.、Kiura Katsuyuki
  • Journal Title: Respiratory Investigation Volume: 57 Issue: 6 Pages: 512-533
  • DOI: 10.1016/j.resinv.2019.06.001
  • Peer Reviewed
• [Journal Article] Predictive value of serum protein levels in patients with advanced non-small cell lung cancer treated with nivolumab (2019)
  • Author(s): Oyanagi Jun、Koh Yasuhiro、Sato Koichi、Mori Keita、Teraoka Shunsuke、Akamatsu Hiroaki、Kanai Kuninobu、Hayata Atsushi、Tokudome Nahomi、Akamatsu Keiichiro、Nakanishi Masanori、Ueda Hiroki、Yamamoto Nobuyuki
  • Journal Title: Lung Cancer Volume: 132 Pages: 107-113
  • DOI: 10.1016/j.lungcan.2019.03.020
  • Peer Reviewed / Open Access
• [Journal Article] Phase I/II Study of Osimertinib With Bevacizumab in EGFR-mutated, T790M-positive Patients With Progressed EGFR-TKIs: West Japan Oncology Group 8715L (WJOG8715L) (2019)
  • Author(s): Akamatsu Hiroaki、Teraoka Shunsuke、Morita Satoshi、Katakami Nobuyuki、Tachihara Motoko、Daga Haruko、Yamamoto Nobuyuki、Nakagawa Kazuhiko
  • Journal Title: Clinical Lung Cancer Volume: 20 Issue: 4 Pages: e492-e494
  • DOI: 10.1016/j.cllc.2019.03.002
  • Peer Reviewed / Open Access
• [Journal Article] The Japanese Lung Cancer Society Guideline for Non-Small Cell Lung Cancer, Stage IV (2019)
  • Author(s): Akamatsu H, Maemondo M, Seto T, Yamamoto N.
  • Journal Title: International Journal of Clinical Oncology Volume: 24 Pages: 731-770
  • Peer Reviewed / Open Access
• [Journal Article] Clinical significance of monitoring EGFR mutation in plasma using multiplexed digital PCR in EGFR mutated patients treated with afatinib (West Japan Oncology Group 8114LTR study). (2019)
  • Author(s): Akamatsu H, Yasuhiro Koh, Isamu Okamoto, Daichi Fujimoto, Akihiro Bessho, Koichi Azuma, Satoshi Morita, Nobuyuki Yamamoto, Kazuhiko Nakagawa
  • Journal Title: Lung Cancer. Volume: 131 Pages: 128-133
  • DOI: 10.1016/j.lungcan.2019.03.021
  • Peer Reviewed / Open Access
• [Journal Article] Genetic Profiling of Non‐Small Cell Lung Cancer at Development of Resistance to First‐ or Second‐Generation EGFR‐TKIs by CAPP‐Seq Analysis of Circulating Tumor DNA (2019)
  • Author(s): Otsubo Kohei、Sakai Kazuko、Takeshita Masafumi、Harada Daijiro、Azuma Koichi、Ota Keiichi、Akamatsu Hiroaki、Goto Koichi、Horiike Atsushi、Kurata Takayasu、Nakagaki Noriaki、Nosaki Kaname、Iwama Eiji、Nakanishi Yoichi、Nishio Kazuto、Okamoto Isamu
  • Journal Title: The Oncologist Volume: 24 Issue: 8 Pages: 1022-1026
  • DOI: 10.1634/theoncologist.2019-0101
  • Peer Reviewed / Open Access
• [Journal Article] Heterogeneous Expression of Programmed Death Receptor-ligand 1 on Circulating Tumor Cells in Patients With Lung Cancer. (2019)
  • Author(s): Koh H, Yagi S, Akamatsu H, Kanai K, Hayata A, Tokudome N, Akamatsu K, Higuchi M, Kanbara H, Nakanishi M, Ueda H, Yamamoto N.
  • Journal Title: Clinical Lung Cancer Volume: 印刷中 Issue: 4 Pages: 270-277.e1
  • DOI: 10.1016/j.cllc.2019.03.004
  • Peer Reviewed / Open Access
• [Journal Article] Osimertinib for patients with EGFR T790M mutation-positive non-small-cell lung cancer and a poor performance status. (2019)
  • Author(s): Nakashima K, Kimura M, Akamatsu H, Daga H, Imai H, Taira T, Ko R, Hisamatsu Y, Nishino K, Sugimoto T, Miyashita Y, Takahashi T.
  • Journal Title: Jpn J Clin Oncol Volume: 印刷中 Issue: 7 Pages: 671-675
  • DOI: 10.1093/jjco/hyz041
  • Peer Reviewed
• [Journal Article] Carboplatin Plus Nab-paclitaxel in Performance Status 2 Patients With Advanced Non-small-cell Lung Cancer. (2019)
  • Author(s): Nakashima K, Akamatsu H, Murakami H, Niwa T, Iwamoto Y, Ozawa Y, Yokoyama T, Shoda H, Yamamoto N, Yoshioka H, Masuda K, Naito T, Mori K, Takahashi T.
  • Journal Title: Anticancer Res. Volume: 39 Issue: 3 Pages: 1463-1468
  • DOI: 10.21873/anticanres.13263
  • Peer Reviewed
• [Journal Article] The impact of high PD-L1 expression on the surrogate endpoints and clinical outcomes of anti-PD-1/PD-L1 antibodies in non-small cell lung cancer. (2019)
  • Author(s): Ito K, Miura S, Sakaguchi T, Murotani K, Horita N, Akamatsu H, Uemura K, Morita S, Yamamoto N.
  • Journal Title: Lung Cancer Volume: 128 Pages: 113-119
  • DOI: 10.1016/j.lungcan.2018.12.023
  • Peer Reviewed
• [Journal Article] A Phase II Study of Nivolumab in Patients With Advanced Non-small-cell Lung Cancer who Responded to Prior PD-1/L1 Inhibitors: West Japan Oncology Group 9616L (WJOG9616L). (2019)
  • Author(s): Akamatsu H, Teraoka S, Koh Y, Yamanaka T, Yamamoto N, Nakagawa K.
  • Journal Title: Clinical Lung Cancer Volume: 20 Issue: 2 Pages: 139-141
  • DOI: 10.1016/j.cllc.2018.12.001
  • Peer Reviewed / Open Access
• [Journal Article] A Phase II Study of Gefitinib With Concurrent Thoracic Radiotherapy in Patients With Unresectable, Stage III Non-small-cell Lung Cancer Harboring EGFR Mutations (WJOG6911L). (2019)
  • Author(s): Akamatsu H, Harada H, Tokunaga S, Yoshimura N, Ikeda H, Oizumi S, Sugimoto N, Takano T, Murakami H, Nishimura Y, Yamamoto N, Nakagawa K.
  • Journal Title: Clinical Lung Cancer Volume: 20 Issue: 1 Pages: e25-e27
  • DOI: 10.1016/j.cllc.2018.08.017
  • Peer Reviewed / Open Access
• [Journal Article] Genetic Profiling of Non-Small Cell Lung Cancer at Development of Resistance to First- or Second-Generation EGFR-TKIs by CAPP-Seq Analysis of Circulating Tumor DNA. (2019)
  • Author(s): Otsubo K, Sakai,K, Takeshita M, Harada D, Azuma K, Ota K, Akamatsu H, Goto K, Horiike A, Kurata T, Nakagaki N, Nosaki K, Iwama E, Nakanishi Y, Nishio N, Okamoto I.
  • Journal Title: The Oncologist Volume: 印刷中
  • Peer Reviewed / Open Access
• [Journal Article] Osimertinib With Ramucirumab in EGFR-mutated, T790M-positive Patients With Progression During EGFR-TKI Therapy: Phase Ib Study (2018)
  • Author(s): Akamatsu H, Koh Y, Ozawa Y, Fujimoto D, Hata A, Katakami N, Tomii K, Shimokawa T, Yamamoto N.
  • Journal Title: Clinical Lung Cancer Volume: 19 Issue: 6 Pages: e871-e874
  • DOI: 10.1016/j.cllc.2018.08.001
  • Peer Reviewed / Open Access
• [Journal Article] Osimertinib in Japanese patients with EGFR T790M mutation-positive advanced non-small-cell lung cancer: AURA3 trial. (2018)
  • Author(s): Akamatsu H, Katakami N, Okamoto I, Kato T, Kim YH, Imamura F, Shinkai M, Hodge RA, Uchida H, Hida T.
  • Journal Title: Lung Cancer Volume: 109 Issue: 6 Pages: 1930-1938
  • DOI: 10.1111/cas.13623
  • NAID: 120006496875
  • Peer Reviewed / Open Access
• [Journal Article] EGFR mutation analysis for prospective patient selection in AURA3 phase III trial of osimertinib versus platinum-pemetrexed in patients with EGFR T790M-positive advanced non-small-cell lung cancer. (2018)
  • Author(s): John T, Akamatsu H, Delmonte A, Su WC, Lee JS, Chang GC, Huang X, Jenkins S, Wu YL.
  • Journal Title: Lung Cancer Volume: 126 Pages: 133-138
  • Peer Reviewed / Int'l Joint Research
• [Journal Article] Exploration of resistance mechanisms for epidermal growth factor receptor-tyrosine kinase inhibitors based on plasma analysis by digital polymerase chain reaction and next-generation sequencing. (2018)
  • Author(s): Iwama E, Sakai K, Azuma K, Harada D, Nosaki K, Hotta K, Nishio M, Kurata T, Fukuhara T, Akamatsu H, Goto K, Shimose T, Kishimoto J, Nakanishi Y, Nishio K, Okamoto I.
  • Journal Title: Cancer Sci Volume: 109 Issue: 12 Pages: 3921-3933
  • DOI: 10.1111/cas.13820
  • Peer Reviewed / Open Access
• [Journal Article] Erlotinib Plus Bevacizumab Phase II Study in Patients with Advanced Non-small-Cell Lung Cancer (JO25567): Updated Safety Results. (2018)
  • Author(s): Kato T, Seto T, Nishio M, Goto K, Yamamoto N, Okamoto I, Tao L, Yu W, Khaznadar T, Tajima K, Shibata M, Seki A, Yamamoto N
  • Journal Title: Drug Saf Volume: 41 Issue: 2 Pages: 229-237
  • DOI: 10.1007/s40264-017-0596-0
  • Peer Reviewed / Open Access
• [Journal Article] Does EGFR Mutation Type Influence Patient-Reported Outcomes in Patients with Advanced EGFR Mutation-Positive Non-Small-Cell Lung Cancer? Analysis of Two Large, Phase III Studies Comparing Afatinib with Chemotherapy (LUX-Lung 3 and LUX-Lung 6). (2018)
  • Author(s): Wu YL, Hirsh V, Sequist LV, Hu CP, Feng J, Lu S, Huang Y, Schuler M, Mok T, Yamamoto N, O’Byrne K, Geater SL, Zhou C, Massey D, Marten A, Lungershausen J, Yang JC
  • Journal Title: Patient Volume: 11 Issue: 1 Pages: 131-141
  • DOI: 10.1007/s40271-017-0287-z
  • Peer Reviewed / Open Access / Int'l Joint Research
• [Journal Article] Real world treatment and outcomes in EGFR mutation-positive non-small cell lung cancer: Long-term follow-up of a large patients cohort. (2018)
  • Author(s): 6.Okamoto I, Morita S, Tashiro N, Imamura F, Inoue A, Seto T, Yamamoto N, Ohe Y, Nakagawa K, Fukuoka M
  • Journal Title: Lung Cancer Volume: 117 Pages: 14-19
  • DOI: 10.1016/j.lungcan.2018.01.005
  • NAID: 120006454679
  • Peer Reviewed / Open Access
• [Journal Article] Analysis of central nervous system efficacy in the J-ALEX study of alectinib versus crizotinib in ALK-positive non-small-cell lung cancer. (2018)
  • Author(s): 9.Nishio M, Nakagawa K, Mitsudomi T, Yamamoto N, Tanaka T, Kuriki H, Zeaiter A, Tamura T:
  • Journal Title: Lung Cancer Volume: 121 Pages: 37-40
  • DOI: 10.1016/j.lungcan.2018.04.015
  • Peer Reviewed / Open Access
• [Journal Article] Afatinib as First-line Treatment of Older Patients With EGFR Mutation-Positive Non-Small-Cell Lung Cancer: Subgroup Analyses of the LUX-Lung 3, LuX-Lung 6, and LUX-Lung 7 Trials. (2018)
  • Author(s): Wu YL, Sequist LV, Tan EH, Geater SL, Orlov S, Zhang L, Lee KH, Tsai CM, Kato T, Barrios CH, Schuler M, Hirsh V, Yamamoto N, O’Byrne K, Boyer M, Mok T, Peil B, Marten A, Chih-Hsin Yang J, Paz-Ares L, Park K
  • Journal Title: Clinical Lung Cancer Volume: 19 Issue: 4 Pages: e465-e479
  • DOI: 10.1016/j.cllc.2018.03.009
  • Peer Reviewed / Open Access / Int'l Joint Research
• [Presentation] ドライバー変異陽性患者における周術期薬物療法 (2021)
  • Author(s): 赤松弘朗
  • Organizer: 第60回日本呼吸器学会総会
  • Invited
• [Presentation] HER2 missense mutations in breast cancer cells do not alter HER2 internalization or sensitivity to T-DM1 (2020)
  • Author(s): Hiroaki Akamatsu, Rosa Mino, Marcel Mettlen, Dan Ye, Dhivya R. Sudhan, Albert Lin, Arnaldo Marin, Alberto Servetto, Kyung-min Lee, Sumanta Chatterjee, Sandra L. Schmid, Carlos L. Arteaga and Ariella B. Hanker
  • Organizer: AACR Annual Meeting 2020
  • Int'l Joint Research
• [Presentation] EGFR遺伝子変異陽性肺腺癌に対するオシメルチニブ＋ラムシルマブの第I相試験（医師主導治験） (2019)
  • Author(s): 小澤雄一、赤松弘朗、洪泰浩、山本信之
  • Organizer: 肺癌学会2019
• [Presentation] Predictive impact of sequential evaluation of PD-L1-expressing circulating tumor cells in NSCLC patients treated with nivolumab. (2018)
  • Author(s): Koh Y, Akamatsu H, Mori K, Kanai K, Hayata A, Tokudome N, Higuchi M, Akamatsu K, Nakanishi M, Ueda H, Yamamoto N
  • Organizer: American Association for Cancer Research Annual Meeting
  • Int'l Joint Research
• [Presentation] Predictive values of serum protein levels in advanced non-small-cell lung cancer patients treated with nivolumab. (2018)
  • Author(s): Oyanagi J, Koh Y, Akamatsu H, Kanai K, Hayata A, Tokudome N, Akamatsu K, Nakanishi M, Ueda H, Yamamoto N:
  • Organizer: American Association for Cancer Research Annual Meeting
• [Presentation] 肺癌診療ガイドライン改訂の要点 (2018)
  • Author(s): 赤松弘朗
  • Organizer: 第58回日本呼吸器学会学術講演会
  • Invited
• [Presentation] 肺癌薬物療法アップデート 肺がんの薬物療法 (2018)
  • Author(s): 赤松弘朗
  • Organizer: 第16回日本臨床腫瘍学会学術集会
  • Invited
• [Presentation] がん免疫療法ガイドライン改訂版 (2018)
  • Author(s): 赤松弘朗
  • Organizer: 第16回日本臨床腫瘍学会学術集会
  • Invited
• [Book] がん免疫療法ガイドライン 第2版 (2019)
  • Author(s): 日本臨床腫瘍学会
  • Total Pages: 148
  • Publisher: 日本肺癌学会
• [Book] 呼吸器疾患最新の治療2019-2020 (2019)
  • Author(s): 杉本武哉, 赤松弘朗, 山本信之
  • Total Pages: 534
  • Publisher: 南江堂
  • ISBN: 9784524245574
• [Book] オンコロジークリニカルガイド 肺癌化学療法 (2019)
  • Author(s): 赤松弘朗
  • Total Pages: 375
  • Publisher: 南山堂
• [Book] Medical Practice, 分子標的薬と血管新生阻害剤 (2019)
  • Author(s): 赤松弘朗
  • Total Pages: 160
  • Publisher: 文光堂
• [Book] 肺癌診療ガイドライン 2018年版 第5版 (2018)
  • Author(s): 赤松弘朗、山本信之、他
  • Total Pages: 420
  • Publisher: 金原出版
  • ISBN: 9784307203913
• [Book] がん免疫療法ガイドライン 第2版 (2018)
  • Author(s): 赤松弘朗、山本信之、他
  • Total Pages: 162
  • Publisher: 金原出版
  • ISBN: 9784307101950